Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium

Emerging Infectious Diseases

Volumn 23, Issue 5, 2017, Pages 809-812

  Murray, Gerald L ^a,b,c   Bradshaw, Catriona S ^a,d,e   Bissessor, Melanie ^d   Danielewski, Jennifer ^b   Garland, Suzanne M ^b,c,e   Jensen, Jørgen S ^f   Fairley, Christopher K ^a,d   Tabrizi, Sepehr N ^b,c,e  

^a MONASH UNIVERSITY   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d ALFRED HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PRISTINAMYCIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; DRUG SUBSTITUTION; FEMALE; GENE MUTATION; GENE SEQUENCE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA GENITALIUM; MYCOPLASMOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; REINFECTION; SEX WORKER; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; AUSTRALIA; BACTERIAL GENE; DRUG EFFECTS; GENETICS; MICROBIOLOGY; MYCOPLASMA INFECTIONS;

ANTI-BACTERIAL AGENTS; AUSTRALIA; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MACROLIDES; MALE; MYCOPLASMA GENITALIUM; MYCOPLASMA INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 85018628132     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2305.161745     Document Type: Article

References (15)

1. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015;61:418–26. http://dx.doi.org/10.1093/cid/civ312
2. Lau A, Bradshaw CS, Lewis D, Fairley CK, Chen MY, Kong FY, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis. 2015;61:1389–99. http://dx.doi.org/10.1093/cid/civ644
3. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010;17:1152–3. http://dx.doi.org/10.1038/nsmb.1892
4. Barnard FM, Maxwell A. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob Agents Chemother. 2001;45:1994–2000. http://dx.doi.org/10.1128/AAC.45.7.1994-2000.2001
5. Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium–infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60:1228–36. http://dx.doi.org/10.1093/cid/ciu1162
6. Couldwell DL, Tagg KA, Jeoffreys NJ, Gilbert GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS. 2013;24:822–8. http://dx.doi.org/10.1177/0956462413502008
7. Kikuchi M, Ito S, Yasuda M, Tsuchiya T, Hatazaki K, Takanashi M, et al. Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan. J Antimicrob Chemother. 2014;69:2376–82. http://dx.doi.org/10.1093/jac/dku164
8. Shimada Y, Deguchi T, Nakane K, Masue T, Yasuda M, Yokoi S, et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance. Int J Antimicrob Agents. 2010;36:255–8. http://dx.doi.org/10.1016/j.ijantimicag.2010.05.011
9. Walker J, Fairley CK, Bradshaw CS, Tabrizi SN, Twin J, Chen MY, et al. Mycoplasma genitalium incidence, organism load, and treatment failure in a cohort of young Australian women. Clin Infect Dis. 2013;56:1094–100. http://dx.doi.org/10.1093/cid/cis1210
10. Tagg KA, Jeoffreys NJ, Couldwell DL, Donald JA, Gilbert GL. Fluoroquinolone and macrolide resistance–associated mutations in Mycoplasma genitalium. J Clin Microbiol. 2013;51:2245–9. http://dx.doi.org/10.1128/JCM.00495-13
11. Deguchi T, Yasuda M, Horie K, Seike K, Kikuchi M, Mizutani K, et al. Drug resistance–associated mutations in Mycoplasma genitalium in female sex workers, Japan. Emerg Infect Dis. 2015;21:1062–4. http://dx.doi.org/10.3201/eid2106.142013
12. Dumke R, Thurmer A, Jacobs E. Emergence of Mycoplasma genitalium strains showing mutations associated with macrolide and fluoroquinolone resistance in the region Dresden, Germany. Diagn Microbiol Infect Dis. 2016;86:221–3. http://dx.doi.org/10.1016/j.diagmicrobio.2016.07.005
13. Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58:631–7. http://dx.doi.org/10.1093/cid/cit752
14. Le Roy C, Hénin N, Pereyre S, Bébéar C. Fluoroquinoloneresistant Mycoplasma genitalium, southwestern France. Emerg Infect Dis. 2016;22:1677–9. http://dx.doi.org/10.3201/eid2209.160446
15. Deguchi T, Maeda S, Tamaki M, Yoshida T, Ishiko H, Ito M, et al. Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother. 2001;48:742–4. http://dx.doi.org/10.1093/jac/48.5.742